The Tesla stock forecast was written by Hugh Camiener, Analyst at I Know First. Bachelor of Arts candidate at Columbia University.
Summary
Dynavax is a commercial state biopharmaceutical company which develops and commercializes vaccines..
Dynavax has an FDA approval on their Hepatitis B vaccine, and they have partnered with Sinovac in developing a vaccine for COVID.
The pandemic has caused a significant decline in Dynavax’s revenue, with their net product revenue falling 71% in comparison to Q2 last year.
Dynavax’s vaccine partnership with Sinovac has shown positive signs in phase 1 and phase 2 of testing, and their vaccine will be entering phase 3 in Brazil.
There is a large amount of volatility in the biopharmaceutical industry; amidst Russia’s self-proclaimed vaccine, Dynavax’s stock fell 9.7%.
Dynavax stock forecast remains a high-risk, high reward option..
Over the period of June 4th to June 18th, Array stock (Array BioPharma Inc., NASDAQ: ARRY) stock price rose by 65.65% following a strong buy rating given by I Know First’s market forecasting algorithm. The Boulder, Colorado-based company primarily focuses their work on discovering, developing, and commercializing small molecule drugs to treat patients with cancer and other diseases. Conducting business in North America, Europe, and the Asia Pacific, the biotechnology firm’s two main drugs, Braftovi and Mektovi, are currently in the market for treating skin-cancer patients who carry certain
OPKO Health, Inc. (NASDAQ: OPK) is a diversified healthcare company. Incorporated on November 18, 1991, the company’s segments include pharmaceutical, diagnostics, and corporate. The company’s pharmaceutical operations
The article was written by Amber Zhou, a Financial Analyst at I Know First.
DVAX Stock Forecast
“We believe there’s a great opportunity for Dynavax to contribute to the overall health of the adult population with diabetes”—said Dr. Rob Janssen, chief medical officer of Dynavax.
(Source: mmm-online.com)
Highlights:
Competitive Edge and Huge Market Potential from Heplisav-B®
Market Doubts about Trial Data of Immuno-Oncology Platform
Enanta also has three clinical stage internally invented and wholly owned programs in areas of high unmet need namely NASH, PBC and RSV. And I would note, all three of these development programs now have fast track designation.
Jay Luly, President and CEO
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493).
(Source: Yahoo Finance)
For the second fiscal quarter ending in March 31st, 2018, Enanta reported revenues of $44 million compared to the $9 million for the same period in 2017. The increase is attributable to the royalties earned on Abbvie’s $919 million sales of hepatitis C virus regimens including MAVIRET. Research and development expenses also increased to $21.5 million in the second fiscal quarter ending in March 31st compared to the $13 million for the same period in 2017. The increase is attributable to the further progression of R&D programs in NASH, PBC, RSV, and HBV, which is showing promising clinical trial results. Net income showed a major improvement to $12.6 million from a net loss of $5.4 million for the same period in 2017.
(Source: Wikimedia Commons)
At the International Liver Congress, 2018, Enanta presented promising clinical trial results for EP-027367 and EDP-305. EP-027367 is one of several core inhibitors Enanta is developing for hepatitis B, and the data showed that in a chimeric SCID mouse model with human liver cells, EP-027367 reduced viral DNA and RNA levels up to 3.0 logs from baseline through 4 weeks of treatment. EDP-305 is Enanta’s FXR agonist in phase 2 studies for both NASH and PBC. Two of the three posters on EDP-305 focused on additional preclinical safety and efficacy data, and the third poster presented data from Enanta’s previously released Phase 1 study. Moreover, the FDA granted Enanta’s EDP-938 fast track designation for RSV, and phase 1 clinical trial is ongoing. Through such promising results in new regimen development, Enanta’s share prices have been constantly increasing for the past year.
On March 8th, I Know First’s algorithm made a bullish forecast on ENTA for a time frame of 3 months. As shown below, the signal strength was 60.13 and the predictability rating was 0.64. In accordance with eh forecasts, ENTA grew by 43.34% by June 8th. The gains of 43.34% during the 3 month period highlight I Know First’s algorithm’s accuracy.
Current I Know First subscribers received this bullish ENTA forecast on March 8th, 2018.
Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.
“Based on the public data on IMMU-132 and available information regarding the Company’s pipeline, I believe the antibody-drug conjugates of Immunomedics have a high likelihood of improving the lives of countless patients with significant unmet medical needs…While the U.S. and global approval and commercialization of IMMU-132 for metastatic triple negative breast cancer are a key goal for me and my team, we simultaneously will be focused on developing IMMU-132 in multiple solid tumor indications, thereby laying the foundation to transform Immunomedics into a recognized leader in the field of antibody-drug conjugates.” – Michael Pehl, President and CEO of Immunomedics
Source: tnbctrial.com
IIMMU actual stock performance since I Know First’s bullish forecast.
Immunomedics, Inc., (NASDAQ:IMMU) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ most advanced product candidate is IMMU-132 (sacituzumab govitecan), an antibody-drug conjugate that has received Breakthrough Therapy Designation from the FDA for the treatment of patients with metastatic triple-negative breast cancer who have failed at least two prior therapies for metastatic disease. Immunomedics’ immediate priority is to commercialize its most advanced product candidate, sacituzumab govitecan (IMMU-132), beginning in the U.S., with metastatic triple-negative breast cancer as the first indication, thus becoming a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. After it announced its quarterly report on May 9th, the stock enjoyed another surge to $24.16, with a price increase of 28.03% by June 8th. The stock is still up-trending.
Analyst growth expectation. Source: Simplywall.st
Total revenues were $0.5 million for the third fiscal quarter ended March 31, 2018 and $1.8 million for the nine months ended March 31, 2018, compared to $1.3 million in the third fiscal quarter ended March 31, 2017 and $2.4 million for the nine months ended March 31, 2017. The decreases were due primarily to lower sales volume of LeukoScan® in Europe, so the company could put its primary focus on ADC business. Total costs and expenses in the third quarter and nine months of fiscal 2018 reached to $38.1 million and $90.4 million respectively due primarily to increases in research and development expenses as well as in sales and marketing expenses. However, in the future, analysts tend to have very bullish prospect on the company’s growth. According to Simply Wall St data, Immunomeics is expected to achieve a revenue growth of 80.2% per year, far exceeding the average level of 16% for biotech companies, and the expected earnings growth could reached to 56.4%, also well above the industry average of 23.4%.
At the short-term liabilities level of US$93.62 million liabilities, it appears that the company has been able to meet these commitments. As of March 31, 2018, the Company had $358.8 million in cash, cash equivalents, and marketable securities which it believes is sufficient to support its next phase of growth and continue operations into 2020. In March 2018, the Phase 3 ASCENT study dosed the first patient in Europe, reflecting the encouraging progress of the confirmatory trial with sacituzumab govitecan in patients with mTNBC. The Company will require additional funding in 2020 to complete its clinical trials currently underway or planned, to continue research and new development programs, to expand commercial applications for sacituzumab govitecan into earlier lines of therapy for mTNBC patients and for patients with other types of cancer indications, such as advanced urothelial cancer and other indications with high, unmet medical need, as a mono and combination therapy, and to continue operations.
Analysts recommendations
Source: Yahoo Finance
Currently, analysts from Yahoo Finance monitoring this stock tend to have the consensus that they would give very bullish forecast on the stock performance. All of three recommendations that analysts have given are buy or hold.
I Know First’s Algorithm Forecast performance for IMMU
On June 6th, 2017, I Know First Algorithm gave very bullish forecast on IMMU, which ranked as the top performing prediction with a return of 210.71%. The predictabilities also showed strong confidence that IMMU stock price was very likely to soar, with one-year predictability of 0.66, which was in accordance the actual stock performance. IMMU has risen 197.54% in the forecasting time period.
Our top-line performance during the first quarter reflects slightly better-than-expected growth in our OUS business driven by solid AFX growth in both the European and CAPLA markets…These accomplishments reinforce Endologix’s
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
